-+ 0.00%
-+ 0.00%
-+ 0.00%

Avalon Pharma Signs 10-year Licensing Agreement With OneSource Specialty Pharma

MT Newswires·10/11/2026 03:27:00
Listen to the news
03:27 AM EDT, 10/11/2026 (MT Newswires) -- Middle East Pharmaceutical Industries Co. (SASE:4016), d/b/a Avalon Pharma, secured an exclusive license from India-based OneSource Specialty Pharma to register and market Tirzepatide multi-dose pen in Saudi Arabia and other markets in the Middle East and North Africa region. The Tadawul-listed pharmaceutical company may also request the transfer of the manufacturing technology following the product's commercialization, according to a Sunday release. The 10-year contract, with automatic one-year renewals, is poised to deliver cumulative revenue of at least 800 million Saudi riyals in the first five years.